RNA · Atrium Therapeutics, Inc.
$13.20
-0.28 (-2.08%)
At close · Aug 21
Market Cap
$225.79M
Shares
17.11M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$13.20
Open$13.53
Day$12.96–13.59
Available close range$11.18–16.54
Avg vol 30d144K
Short int3.5M · 20.5% float · 28.4d
Short vol28%
Last earningsAug 13, 2026
DataFeb 2026–Aug 2026
Filing10-Q · Aug 13
The closing range uses available history since Feb 27, 2026; less than a full year is stored.
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 13, 2026
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Buy
Momentum
Weak
Sentiment
Neutral
Fundamentals
Limited
Quant / Vol
Moderate
Market backdrop
VIX 15.1 · calm
Equity put/call 0.51
Technical
price trend
50 / 200-day cross
No cross
Price vs 50-day avg
+6%
above
RSI (14)
61
neutral
MACD trend
Positive
52-week position
38%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+15%
trailing
6-month return
−11%
trailing
Relative strength
−23%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50/200-day averages unavailable
Institutional flow
Distributing
-6% holders QoQ · +38 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
20.54% of float · ▼ -2.1% MoM · 28.4 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
155 holders — 13F breadth
Squeeze score
76
high risk · 0–100
Fundamentals
Not enough data for a confident read.
Quant / Vol
risk profile
Volatility
45%
annualized · 1-yr
Max drawdown
−32%
past year
ATR
3.7%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 50-day avg
+6%
Bullish
RSI (14)
61
Neutral
MACD trend
Positive
Bullish
52-week position
38%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50/200-day averages unavailable
Institutional flow
Distributing
-6% holders QoQ · +38 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
20.54% of float · ▼ -2.1% MoM · 28.4 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
155 holders — 13F breadth
Price context
position in its available closing range
Range low $11
Now $13 · 38%
Range high $17
vs 50-day avg +6%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
RNA
this stock
Atrium Therapeutics, Inc.
|
$225.79M | — | — | — | 20.5% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$138.91B | +20.9% | +46.2% | 31.9 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$85.87B | +8.1% | +20.8% | 20.7 | 3.3% |
|
ARGX
Argenx SE
|
$64.66B | +23.6% | — | — | 2.1% |
|
CSLLY
Csl Ltd
|
$58.31B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| RNA | +2.8% | +14.9% | -11.5% | +16.3% | — |
| SPY | -1.4% | +3.6% | +11.6% | +2.5% | +12.3% |
| vs SPY | +4.2% | +11.3% | -23.0% | +13.8% | — |
Key facts
CIK
2093101
CUSIP
04965N104
13F (30d)
149 filings
146 filers
Visit website
Investor relations